<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256204</url>
  </required_header>
  <id_info>
    <org_study_id>TVP-1012/500 (ADAGIO)</org_study_id>
    <nct_id>NCT00256204</nct_id>
  </id_info>
  <brief_title>A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease</brief_title>
  <acronym>ADAGIO</acronym>
  <official_title>A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2 phase study to evaluate disease progression in Parkinson's disease patients taking
      rasagiline
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline</measure>
    <time_frame>12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w</time_frame>
    <description>The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase</measure>
    <time_frame>36 weeks</time_frame>
    <description>Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1174</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1mg rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2mg rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each arm is followed by 36 weeks of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline Mesylate</intervention_name>
    <description>tablet, 1mg once daily</description>
    <arm_group_label>1mg rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline Mesylate</intervention_name>
    <description>tablet, 2mg once daily</description>
    <arm_group_label>2mg rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with idiopathic PD whose diagnosis is confirmed at screening, with at
             least two cardinal signs without any other known or suspected cause of parkinsonism.
             If tremor is not present, subjects must have unilateral onset and persistent
             asymmetry.

          -  Subjects with a diagnosis of early idiopathic PD of less than 1½ years duration from
             time of documented diagnosis.

          -  Subjects whose clinical condition at the time of enrollment does not require anti-PD
             treatment and will not require for the next 9 months.

          -  Willing and able to give informed consent.

        Exclusion Criteria:

          -  Subjects younger than 30 or older than 80 years.

          -  Subjects with loss of postural reflexes.

          -  Subjects with UPDRS Tremor score of 3 or greater in any limb.

          -  Subjects with Hoehn &amp;Yahr Stage III or greater at screening.

          -  Subjects with freezing while walking.

          -  Subjects with any of the following features that tend to exclude PD as the cause of
             Parkinsonism:

          -  History of repeated strokes with stepwise progression of Parkinsonian features

          -  History of repeated head injury or history of definite encephalitis

          -  Sustained remission

          -  Supranuclear gaze palsy

          -  Cerebellar signs

          -  Early severe autonomic involvement

          -  Babinski's sign

          -  Presence of a cerebral tumour or communicating hydrocephalus

          -  MPTP exposure

          -  Oculogyric crises

          -  Subjects who have had previous use of rasagiline or selegiline

          -  Subjects having used other anti-PD medication basis at any time prior to baseline

          -  Subjects having used other anti-PD medication (including anticholinergics) for less
             than 3 weeks during the 3 month period prior to baseline. (not including a single
             L-Dopa dose as part of L-Dopa test)

          -  Subjects having used any other anti-PD medication (including anticholinergics) for
             less than 3 weeks prior to the 3 month period preceding baseline whose anti-PD
             medication is intentionally ceased in order for the subject to enter the study.

          -  Subjects who have a clinically significant or unstable medical or surgical condition
             that may preclude safe and complete participation

          -  Hypertensive subjects whose BP is not well controlled according to the medical record
             or as observed during the week of home BP recording prior to baseline

          -  Subjects diagnosed with melanoma based on the screening dermatologic examination, or
             with a history of melanoma. Subjects with suspicious lesions at baseline who do not
             undergo biopsy

          -  Subjects with significant cognitive impairment as defined by MMSE score &lt; 26

          -  Subjects with clinically significant psychiatric illness, including major depression
             [Beck Depression Inventory (short form) ≥15

          -  Subjects with a history of alcohol or substance abuse within the past 2 years

          -  Subjects who have taken any experimental medications within 60 days prior to baseline

          -  Subjects who have used coenzyme Q10 (in daily doses &gt; 300 mg) within 120 days prior to
             baseline

          -  Subjects who have used sympathomimetics (including over-the-counter remedies - nasal
             or oral), dextromethorphan, pethidine or St. John's Wort within the 7 days prior to
             baseline

          -  Subjects who have used antidepressants within 42 days prior to baseline

          -  Subjects who have used ciprofloxacin, a potent CYP 1A2 inhibitor within 7 days prior
             to baseline

          -  Subjects who have used MAO inhibitors including reserpine or methyldopa within the
             three months prior to baseline, or treatment with an anti-emetic or antipsychotic
             medication with central dopamine antagonist activity within the six months prior to
             baseline

          -  Women who are not postmenopausal, surgically sterilized, or using adequate birth
             control [oral birth control pills, IUD, or a long acting injectable form of
             contraception; barrier methods alone (i.e., condom) are not sufficient]. Women of
             childbearing potential without a negative pregnancy test at screening. Nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoni Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceutical Industries</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.tevaneuro.com</url>
    <description>For more information about Teva Neuroscience</description>
  </link>
  <link>
    <url>http://www.mdvu.org/library/ratingscales/pd/updrs.pdf</url>
    <description>Unified Parkinsons Disease Ratings Scale</description>
  </link>
  <link>
    <url>http://en.wikipedia.org/wiki/Unified_Parkinson's_Disease_Rating_Scale</url>
    <description>Unified Parkinson's Disease Rating Scale</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>March 8, 2010</results_first_submitted>
  <results_first_submitted_qc>May 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's</keyword>
  <keyword>Rasagiline Mesylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1mg Delayed Start</title>
          <description>1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
        </group>
        <group group_id="P2">
          <title>1mg Early Start</title>
          <description>1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
        </group>
        <group group_id="P3">
          <title>2mg Delayed Start</title>
          <description>2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
        </group>
        <group group_id="P4">
          <title>2mg Early Start</title>
          <description>2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="288"/>
                <participants group_id="P3" count="295"/>
                <participants group_id="P4" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="241"/>
                <participants group_id="P4" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need for additional prohibited treatment</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1mg Delayed Start</title>
          <description>1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
        </group>
        <group group_id="B2">
          <title>1mg Early Start</title>
          <description>1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
        </group>
        <group group_id="B3">
          <title>2mg Early Start</title>
          <description>2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
        </group>
        <group group_id="B4">
          <title>2mg Delayed Start</title>
          <description>2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="298"/>
            <count group_id="B2" value="288"/>
            <count group_id="B3" value="293"/>
            <count group_id="B4" value="295"/>
            <count group_id="B5" value="1174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="9.6"/>
                    <measurement group_id="B2" value="62.4" spread="9.7"/>
                    <measurement group_id="B3" value="62.3" spread="9.6"/>
                    <measurement group_id="B4" value="62.4" spread="9.7"/>
                    <measurement group_id="B5" value="62.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="182"/>
                    <measurement group_id="B5" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline</title>
        <description>The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
        <time_frame>12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1mg Delayed Start</title>
            <description>1mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
          </group>
          <group group_id="O2">
            <title>1mg Early Start</title>
            <description>1mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
          </group>
          <group group_id="O3">
            <title>2mg Early Start</title>
            <description>2mg Rasagiline tablet QD early start active treatment arm (72 weeks active)</description>
          </group>
          <group group_id="O4">
            <title>2mg Delayed Start</title>
            <description>2mg Rasagiline tablet QD 36 week delayed start active treatment arms (36 weeks placebo followed by 36 weeks Rasagiline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline</title>
          <description>The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="4.9"/>
                    <measurement group_id="O2" value="-1.2" spread="5.6"/>
                    <measurement group_id="O3" value="-0.7" spread="4.8"/>
                    <measurement group_id="O4" value="0.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.5"/>
                    <measurement group_id="O2" value="-1.1" spread="5.6"/>
                    <measurement group_id="O3" value="-0.5" spread="5.6"/>
                    <measurement group_id="O4" value="2.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="7.2"/>
                    <measurement group_id="O2" value="0.6" spread="5.9"/>
                    <measurement group_id="O3" value="0.8" spread="6.5"/>
                    <measurement group_id="O4" value="3.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.4"/>
                    <measurement group_id="O2" value="0.2" spread="6.7"/>
                    <measurement group_id="O3" value="0.4" spread="7.2"/>
                    <measurement group_id="O4" value="1.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="6.9"/>
                    <measurement group_id="O2" value="0.7" spread="7.0"/>
                    <measurement group_id="O3" value="0.5" spread="7.1"/>
                    <measurement group_id="O4" value="1.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="7.3"/>
                    <measurement group_id="O2" value="0.7" spread="7.1"/>
                    <measurement group_id="O3" value="0.8" spread="7.2"/>
                    <measurement group_id="O4" value="1.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="7.5"/>
                    <measurement group_id="O2" value="1.1" spread="7.3"/>
                    <measurement group_id="O3" value="1.2" spread="7.9"/>
                    <measurement group_id="O4" value="1.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="8.1"/>
                    <measurement group_id="O2" value="1.5" spread="7.7"/>
                    <measurement group_id="O3" value="1.5" spread="8.0"/>
                    <measurement group_id="O4" value="2.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="8.9"/>
                    <measurement group_id="O2" value="1.9" spread="8.1"/>
                    <measurement group_id="O3" value="2.2" spread="8.1"/>
                    <measurement group_id="O4" value="2.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #1: Slopes Superiority of 1mg Rasagiline over Placebo in the PC Phase Where slope is the model estimate of the change from baseline in total UPDRS per week.
In this analysis, all available post-baseline observations in the PC Phase of the trial are analyzed (ITT efficacy data analysis set, weeks 12, 24 and 36). The placebo groups for rasagiline 1mg (delayed-start) and 2mg (delayed-start)are combined to one placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>Repeated Measures Mixed Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #1: Slopes Superiority of 2mg Rasagiline over Placebo in the PC Phase Where slope is the model estimate of the change from baseline in total UPDRS per week.
In this analysis, all available post-baseline observations in the PC Phase of the trial are analyzed (ITT efficacy data analysis set, weeks 12, 24 and 36). The placebo groups for rasagiline 1mg (delayed-start)and 2mg (delayed-start) are combined to one placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Repeated Measures Mixed Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #2: Superiority of Early over Delayed Start at Week 72 In this analysis, observations of subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active-treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0250</p_value>
            <p_value_desc>The analysis was performed on separate datasets and not on the combined dataset as was pre-specified to account for unexpected interactions of dose level by baseline UPDRS and of dose level by center .</p_value_desc>
            <method>Repeated Measures</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #2:Superiority of Early over Delayed Start at Week 72 In this analysis, observations of subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active-treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set.)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6028</p_value>
            <p_value_desc>The analysis was performed on separate datasets and not on the combined dataset as was pre-specified to account for unexpected interactions of dose level by baseline UPDRS and of dose level by center</p_value_desc>
            <method>Repeated Measures</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #3: Slopes Non-Inferiority of Early Start over Delayed Start in the Active Phase.
Where slope is the model estimate of the change from baseline in total UPDRS per week. In this analysis, observations of all subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-Inf Test for difference in slopes between treatment groups. One sided 95% CI calculated for difference between slopes of the 1mg early-start group and the 1mg delayed-start group. The inferiority null hypothesis of the early-start group slope over delayed-start group slope is rejected, if the upper limit of one sided 95% CI for difference in slopes does not cross non-inferiority margin of 0.15 UPDRS points per week.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>0.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.036</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis #3: Slopes Non-Inferiority of Early Start over Delayed Start in the Active Phase.
Where slope is the model estimate of the change from baseline in total UPDRS per week. In this analysis, observations of all subjects entering the active phase with at least 24 weeks of treatment during the PC Phase and at least one available Total UPDRS measurement during the active treatment phase from weeks 48, 54, 60, 66 or 72, are analyzed (ACTE data analysis set).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-Inf Test for difference in slopes between treatment groups. One sided 95% CI calculated for difference between slopes of the 2mg early-start group and the 2mg delayed-start group. The inferiority null hypothesis of the early-start group slope over delayed-start group slope is rejected, if the upper limit of one sided 95% CI for difference in slopes does not cross non-inferiority margin of 0.15 UPDRS points per week.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>0.029</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase</title>
        <description>Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1mg Delayed Start</title>
            <description>+ 2 mg Delayed Start: 36 week combined placebo group.</description>
          </group>
          <group group_id="O2">
            <title>1mg Early Start</title>
            <description>1mg early start active treatment arm (72 weeks active)</description>
          </group>
          <group group_id="O3">
            <title>2mg Early Start</title>
            <description>2mg early start active treatment arm (72 weeks active)</description>
          </group>
          <group group_id="O4">
            <title>2mg Delayed Start</title>
            <description>+1mg Delayed Start: see 1st column</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase</title>
          <description>Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="7.2"/>
                    <measurement group_id="O2" value="1.0" spread="6.0"/>
                    <measurement group_id="O3" value="0.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The adjusted means of the changes in Total UPDRS from baseline to LOV in the placebo-controlled phase, observed in the 1 mg and 2 mg rasagiline early-start groups are compared (two contrasts) to the combined placebo group (1 mg and 2 mg rasagiline delayed-start groups), by applying an Analysis of Covariance model. The model includes treatment group, center and baseline Total UPDRS as covariates. For this analysis, both delayed start arms are pooled as a 'placebo arm'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.857</ci_lower_limit>
            <ci_upper_limit>-2.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The adjusted means of the changes in Total UPDRS from baseline to LOV in the placebo-controlled phase, observed in the 1 mg and 2 mg rasagiline early-start groups are compared (two contrasts) to the combined placebo group (1 mg and 2 mg rasagiline delayed-start groups), by applying an Analysis of Covariance model. The model includes treatment group, center and baseline Total UPDRS as covariates.
For this analysis, both delayed start arms are pooled as a 'placebo arm'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.004</ci_lower_limit>
            <ci_upper_limit>-2.305</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 6 months</time_frame>
      <desc>Each Delayed Start arm was preceded by 36 weeks placebo followed by 36 weeks Rasagiline either 1mg or 2mg; therefore, the placebo groups were combined into one group for the placebo analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Combined Group</title>
          <description>1mg &amp; 2mg combined placebo group includes those patients in 1mg Delayed start and the 2mg Delayed start arms who received placebo for the first 36 weeks.</description>
        </group>
        <group group_id="E2">
          <title>1mg Active Treatment</title>
          <description>1mg Active &amp; 1mg Delayed. This group includes those patients who received 1mg Rasagiline in both the early start active treatment arm (72 weeks active)and those patients who transitioned to active treatment in the 1mg Delayed start treatment arm (36 weeks active treatment)</description>
        </group>
        <group group_id="E3">
          <title>2mg Active Treatment</title>
          <description>2mg Active &amp; 2mg Delayed. This group includes those patients who received 2mg Rasagiline in both the early start active treatment arm (72 weeks active)and those patients who transitioned to active treatment in the 2mg Delayed start treatment arm (36 weeks active treatment)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="593"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Eyelid Ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Retinal Vein Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Parasthesia Oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Heus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Peridiverticular Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Lower respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram Coronary Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Muscle Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Thyroid Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer Stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Metastic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Benign Laryngeal Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Rectal cancer Metastic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Ovarian Epithelial Cancer Metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Prostrate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Akinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hallucination, Visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal Leukoplakia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Pulmonary Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia Facial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Open reduction of fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Incisional Hernia Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Knee Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Colon Polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Abdominal Operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Arterial Stent Insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Coronary Angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hip Arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hip Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Transurethral Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="593"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="593"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="593"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="593"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="288"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="593"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="288"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should the Oversight Committee wish to publish the results of this study, the Oversight Committee agrees to provide Teva with a manuscript for review 60 days prior to submission for publication. Teva retains the right to delete from the manuscript confidential information and to object to suggested publication and/or its timing (at the sole discretion of Teva).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dennis Ahern, MS, Director</name_or_title>
      <organization>Teva Branded Pharmaceutical Products R&amp;D</organization>
      <phone>215-293-6339</phone>
      <email>dennis.ahern@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

